Pre-market most active: ALNEV.PA Neovacs Euronext €0.0008 24 Mar 2026: monitor

ALNEV.PA stock is trading pre-market at €0.0008 on 24 Mar 2026 after a one-day decline of -11.11%. We highlight heavy activity on Euronext with 35,245,238 shares changing hands versus an average volume of 16,097,961, a relative volume of 2.19. This activity puts Neovacs S.A. (ALNEV.PA) among the most active pre-market names in Europe and raises liquidity and execution risk for small orders. Investors should weigh the biotech pipeline and balance-sheet metrics against extreme price volatility in the pre-market session.

ALNEV.PA stock: Pre-market price action and liquidity

Neovacs S.A. (ALNEV.PA) opened pre-market at €0.0009 and trades now at €0.0008, a -11.11% move from the prior close of €0.0009. The stock’s volume of 35,245,238 is well above the 50-day average, signaling unusual interest.

High relative volume can create outsized intraday swings in ALNEV.PA stock and widen spreads, so execution cost and slippage are material concerns for traders during the pre-market session.

ALNEV.PA stock: Fundamentals, valuation and balance sheet

Neovacs reports a market capitalization of €381.00 and negative EPS of -221.36, reflecting persistent losses while the company funds clinical programs. The company shows cash per share €2.50 and book value per share €103.50, but shares outstanding are only 476,625, producing distorted per-share metrics.

Key ratios highlight risk: current ratio 0.63 and research spending at 10.94% of revenue. ALNEV.PA stock’s reported price-to-sales ratio is near zero and price-to-book is effectively negligible, indicating market pricing that does not reflect reported book metrics.

ALNEV.PA stock: Technical snapshot and volatility

Technicals show an oversold momentum profile: RSI 13.43 and CCI -123.23, while ADX at 56.18 indicates a strong trend. The price is far below the 50-day average €0.00253 and the 200-day average €0.50602, underlining the sharp downtrend and historical price dispersion.

Year range is extreme: year high €130.00 and year low €0.0007, which reflects past corporate actions and thin liquidity rather than normal trading behavior. Traders should expect sharp percentage moves and low liquidity at current ticks.

ALNEV.PA stock: Pipeline, news flow and catalysts

Neovacs develops Kinoid therapeutic vaccines including IFNa Kinoid in Phase IIb for systemic lupus erythematosus and earlier-stage programs for dermatomyositis and age-related conditions. Clinical readouts and regulatory updates remain the primary catalysts for ALNEV.PA stock.

Recent market coverage and quotes appear on Investing.com; for company price and chart updates see Investing.com – Neovacs SA and comparative listings at Investing.com Pro. No recent earnings announcement has been posted since 2019, increasing event risk tied to clinical milestones.

ALNEV.PA stock: Meyka AI grade, model forecast and trading guidance

Meyka AI rates ALNEV.PA with a score of 61.99 out of 100: Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly target of €0.04, compared with the current price €0.0008, implying an upside of roughly 4,900%. Forecasts are model-based projections and not guarantees. Given the extreme dispersion between current price and the forecast, risk management, position size limits, and strict stop-loss rules are essential for traders considering ALNEV.PA stock.

Final Thoughts

ALNEV.PA stock is a highly active pre-market name on Euronext with €0.0008 last trade and a volume surge that demands caution. Fundamentals show heavy operating losses (EPS -221.36) and low current liquidity (current ratio 0.63), while technicals are deeply oversold (RSI 13.43) and trend strength is high (ADX 56.18). Meyka AI rates ALNEV.PA 61.99/100 (Grade B, HOLD) and flags clinical catalysts and illiquidity as the dominant drivers. Meyka AI’s forecast model projects a monthly target of €0.04, an implied upside near 4,900%, though such model outputs reflect theoretical scenarios rather than guaranteed outcomes. For most investors, position sizing, clear exit rules, and monitoring of clinical news and volume are essential; speculative traders may view event-driven spikes as the only near-term opportunity. This report is produced by Meyka AI, an AI-powered market analysis platform, and is informational only—not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.